Alzamend Neuro, Inc.
ALZN
$2.15
-$0.05-2.27%
NASDAQ
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.33% | 39.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -63.04% | 137.09% | |||
| Operating Income | 63.04% | -137.09% | |||
| Income Before Tax | 62.97% | -137.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 62.97% | -137.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 62.97% | -137.20% | |||
| EBIT | 63.04% | -137.09% | |||
| EBITDA | 63.69% | -137.28% | |||
| EPS Basic | 76.93% | 47.23% | |||
| Normalized Basic EPS | 76.94% | 19.89% | |||
| EPS Diluted | 76.93% | 47.23% | |||
| Normalized Diluted EPS | 76.94% | 19.89% | |||
| Average Basic Shares Outstanding | 60.54% | 196.08% | |||
| Average Diluted Shares Outstanding | 60.54% | 196.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||